| Abstrakt: |
A recent study conducted by researchers from the Department of Medical Oncology in Italy explored the use of cabozantinib, a medication used in the treatment of advanced or metastatic renal cell carcinoma (RCC). The study analyzed data from an integrated administrative database covering approximately 6.9 million Italian individuals. The findings revealed that 53.1% of patients were highly adherent to cabozantinib therapy, with a median treatment duration of 8.7 months. The study also examined the economic burden of RCC in Italy, with an average total cost per patient of €32,508 during the first year of follow-up. This research provides valuable insights into real-world treatment patterns and costs associated with cabozantinib for RCC. [Extracted from the article] |
